Sleep is essential for a person’s health, and people who feel tired on occasion often boost their energy levels by taking a nap or ensuring restful shut-eye the next evening. But when sleep doesn't ...

Idiopathic hypersomnia treatment should be determined based on factors like symptom profile, age, comorbidities, and additional medications, says review. Treatments to manage idiopathic hypersomnia ...

LUMRYZ is only currently approved for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and Avadel does not market, promote or offer patient support services ...

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine, discusses diagnostic components of idiopathic hypersomnia and ...

Idiopathic hypersomnia is characterized by excessive daytime sleepiness. It is often mistaken for narcolepsy. In addition to its psychiatric symptoms, it can overlap with narcolepsy and affect the ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug exclusivity for JZP258, an oral low-sodium oxybate solution for the treatment of ...

Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to ...

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative ...

Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — Treatment with Xywav was effective in addressing symptoms of idiopathic hypersomnia, regardless ...

ZURICH, SWITZERLAND / ACCESSWIRE / March 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

Tired man sitting at desk in modern office Serdexmethylphenidate is a proprietary prodrug of d-methylphenidate. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global idiopathic hypersomnia treatment market is estimated to be valued at US$ 242.4 million in 2020 and is expected to exhibit a ...